Patient Clinical and Immunologic Data
| Total no. | 64 |
| MM | 44 |
| Active | 26 |
| Average age (median, range) | 62 yr (64.5, 44-84) |
| Men/women | 16/10 |
| M-component IgG/IgA/IgD/κ or λ | 16/8/1/1 |
| Diagnosis | 10 |
| Stage I/II/III; A/B* | 1/1/8; 7/3 |
| Relapse† | 10 |
| Progression‡ | 6 |
| Nonactive | 18 |
| Average age (median, range) | 64 yr (68, 42-81) |
| Men/women | 12/6 |
| M-component IgG/IgA/κ or λ | 12/5/1 |
| Response | 11 |
| Plateau1-153 | 7 |
| MGUS | 20 |
| Average age (median, range) | 66 yr (63.5, 47-89) |
| Men/women | 12/8 |
| M-component IgG/IgA/IgM/κ or λ | 16/2/1/1 |
| Total no. | 64 |
| MM | 44 |
| Active | 26 |
| Average age (median, range) | 62 yr (64.5, 44-84) |
| Men/women | 16/10 |
| M-component IgG/IgA/IgD/κ or λ | 16/8/1/1 |
| Diagnosis | 10 |
| Stage I/II/III; A/B* | 1/1/8; 7/3 |
| Relapse† | 10 |
| Progression‡ | 6 |
| Nonactive | 18 |
| Average age (median, range) | 64 yr (68, 42-81) |
| Men/women | 12/6 |
| M-component IgG/IgA/κ or λ | 12/5/1 |
| Response | 11 |
| Plateau1-153 | 7 |
| MGUS | 20 |
| Average age (median, range) | 66 yr (63.5, 47-89) |
| Men/women | 12/8 |
| M-component IgG/IgA/IgM/κ or λ | 16/2/1/1 |
According to Durie and Salmon.11
Relapse defined as M-component increasing by >50% from the lowest value, or clinical and bone marrow relapse when the M-component did not reflect tumor load and disease activity. Three patients displayed extramedullary localizations: one, left kidney; one, retrobulbar tissue; one, blood.
Two patients displayed extramedullary localizations: one, skin; one, blood.
Plateau phase defined as posttreatment M-component decreasing by >50%, and lasting for at least 6 months without treatment.